Mosaic H5 hemagglutinin provides broad humoral and cellular immune responses against influenza viruses

Journal of Virology

Volumn 90, Issue 15, 2016, Pages 6771-6783

  Kamlangdee, Attapon ^a   Kingstad Bakke, Brock ^a   Osorio, Jorge E ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; HEMAGGLUTININ; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COMPUTER MODEL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE EXPRESSION; H5M GENE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IN VIVO STUDY; INFLUENZA A; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H5N1); INFLUENZA A VIRUS/VIETNAM/1203/04; INFLUENZA VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; T LYMPHOCYTE; VACCINATION; VIRUS GENE; WEIGHT REDUCTION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; IMMUNOLOGY; METABOLISM; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; VACCINIA VIRUS; VIROLOGY;

ANIMALS; ANTIBODIES, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; IMMUNITY, CELLULAR; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; VACCINATION; VACCINIA VIRUS;

EID: 84982793426     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00730-16     Document Type: Article

References (35)

1. Anonymous. 2014. Summary analysis of 2014 survey of National Influenza Centres in the WHO Global Influenza Surveillance and Response System. Wkly Epidemiol Rec 89:369-376.
2. Kingstad-Bakke B, Kamlangdee A, Osorio JE. 2015. Mucosal administration of raccoonpox virus expressing highly pathogenic avian H5N1 influenza neuraminidase is highly protective against H5N1 and seasonal influenza virus challenge. Vaccine 33:5155-5162. http://dx.doi.org/10.1016/j.vaccine.2015.08.005.
3. Osterholm MT, Kelley NS, Sommer A, Belongia EA. 2012. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 12:36-44. http://dx.doi.org/10.1016/S1473-3099(11)70295-X.
4. Krammer F. 2015. Emerging influenza viruses and the prospect of a universal influenza virus vaccine. Biotechnol J 10:690-701. http://dx.doi.org/10.1002/biot.201400393.
5. Krammer F, Pica N, Hai R, Margine I, Palese P. 2013. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J Virol 87:6542-6550. http://dx.doi.org/10.1128/JVI.00641-13.
6. Krammer F. 2015. The quest for a universal flu vaccine: headless HA 2.0. Cell Host Microbe 18:395-397. http://dx.doi.org/10.1016/j.chom.2015.10.003.
7. De Filette M, Min Jou W, Birkett A, Lyons K, Schultz B, Tonkyro A, Resch S, Fiers W. 2005. Universal influenza A vaccine: optimization of M2-based constructs. Virology 337:149-161. http://dx.doi.org/10.1016/j.virol.2005.04.004.
8. De Filette M, Martens W, Roose K, Deroo T, Vervalle F, Bentahir M, Vandekerckhove J, Fiers W, Saelens X. 2008. An influenza A vaccine based on tetrameric ectodomain of matrix protein 2. J Biol Chem 283: 11382-11387. http://dx.doi.org/10.1074/jbc.M800650200.
9. Chen MW, Cheng TJ, Huang Y, Jan JT, Ma SH, Yu AL, Wong CH, Ho DD. 2008. A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses. Proc Natl Acad Sci USA 105:13538-13543. http://dx.doi.org/10.1073/pnas.0806901105.
10. Barouch DH, O'Brien KL, Simmons NL, King SL, Abbink P, Maxfield LF, Sun YH, La Porte A, Riggs AM, Lynch DM, Clark SL, Backus K, Perry JR, Seaman MS, Carville A, Mansfield KG, Szinger JJ, Fischer W, Muldoon M, Korber B. 2010. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 16:319-323. http://dx.doi.org/10.1038/nm.2089.
11. Fischer W, Perkins S, Theiler J, Bhattacharya T, Yusim K, Funkhouser R, Kuiken C, Haynes B, Letvin NL, Walker BD, Hahn BH, Korber BT. 2007. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med 13:100-106. http://dx.doi.org/10.1038/nm1461.
12. Kamlangdee A, Kingstad-Bakke B, Anderson TK, Goldberg TL, Osorio JE. 2014. Broad protection against avian influenza using a modified vaccinia Ankara virus expressing a mosaic hemagglutinin gene. J Virol 88: 13300-13309. http://dx.doi.org/10.1128/JVI.01532-14.
13. Kamili S, Spelbring J, Carson D, Krawczynski K. 2004. Protective efficacy of hepatitis E virus DNA vaccine administered by gene gun in the cynomolgus macaque model of infection. J Infect Dis 189:258-264. http://dx.doi.org/10.1086/380801.
14. Brewoo JN, Powell TD, Jones JC, Gundlach NA, Young GR, Chu H, Das SC, Partidos CD, Stinchcomb DT, Osorio JE. 2013. Cross-protective immunity against multiple influenza virus subtypes by a novel modified vaccinia Ankara (MVA) vectored vaccine in mice. Vaccine 31: 1848-1855. http://dx.doi.org/10.1016/j.vaccine.2013.01.038.
15. Okuno Y, Isegawa Y, Sasao F, Ueda S. 1993. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J Virol 67:2552-2558.
16. Sakabe S, Iwatsuki-Horimoto K, Horimoto T, Nidom CA, Le M, Takano R, Kubota-Koketsu R, Okuno Y, Ozawa M, Kawaoka Y. 2010. A cross-reactive neutralizing monoclonal antibody protects mice from H5N1 and pandemic (H1N1) 2009 virus infection. Antiviral Res 88:249-255. http://dx.doi.org/10.1016/j.antiviral.2010.09.007.
17. Florek NW, Weinfurter JT, Jegaskanda S, Brewoo JN, Powell TD, Young GR, Das SC, Hatta M, Broman KW, Hungnes O, Dudman SG, Kawaoka Y, Kent SJ, Stinchcomb DT, Osorio JE, Friedrich TC. 2014. Modified vaccinia virus Ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques. J Virol 88:13418-13428. http://dx.doi.org/10.1128/JVI.01219-14.
18. Hessel A, Schwendinger M, Holzer GW, Orlinger KK, Coulibaly S, Savidis-Dacho H, Zips ML, Crowe BA, Kreil TR, Ehrlich HJ, Barrett PN, Falkner FG. 2011. Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunity. PLoS One 6: e16247. http://dx.doi.org/10.1371/journal.pone.0016247.
19. Kaur K, Sullivan M, Wilson PC. 2011. Targeting B cell responses in universal influenza vaccine design. Trends Immunol 32:524-531. http://dx.doi.org/10.1016/j.it.2011.08.007.
20. Sun J, Braciale TJ. 2013. Role of T cell immunity in recovery from influenza virus infection. Curr Opin Virol 3:425-429. http://dx.doi.org/10.1016/j.coviro.2013.05.001.
21. + T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP M1. Clin Infect Dis 52:1-7. http://dx.doi.org/10.1093/cid/ciq015.
22. Cargnelutti DE, Sanchez MV, Mattion NM, Scodeller EA. 2013. Development of a universal CTL-based vaccine for influenza. Bioengineered 4:374-378. http://dx.doi.org/10.4161/bioe.23573.
23. Bodewes R, Kreijtz JH, Baas C, Geelhoed-Mieras MM, de Mutsert G, van Amerongen G, van den Brand JM, Fouchier RA, Osterhaus AD, Rimmelzwaan GF. 2009. Vaccination against human influenza A/H3N2 virus prevents the induction of heterosubtypic immunity against lethal infection with avian influenza A/H5N1 virus. PLoS One 4: e5538. http://dx.doi.org/10.1371/journal.pone.0005538.
24. Bodewes R, Kreijtz JH, Geelhoed-Mieras MM, van Amerongen G, Verburgh RJ, van Trierum SE, Kuiken T, Fouchier RA, Osterhaus AD, Rimmelzwaan GF. 2011. Vaccination against seasonal influenza A/H3N2 virus reduces the induction of heterosubtypic immunity against influenza A/H5N1 virus infection in ferrets. J Virol 85:2695-2702. http://dx.doi.org/10.1128/JVI.02371-10.
25. + T-cell responses in mice. J Gen Virol 91:1743-1753. http://dx.doi.org/10.1099/vir.0.020784-0.
26. Bodewes R, Kreijtz JH, van Amerongen G, Geelhoed-Mieras MM, Verburgh RJ, Heldens JG, Bedwell J, van den Brand JM, Kuiken T, van Baalen CA, Fouchier RA, Osterhaus AD, Rimmelzwaan GF. 2010. A single immunization with CoVaccine HT-adjuvanted H5N1 influenza virus vaccine induces protective cellular and humoral immune responses in ferrets. J Virol 84:7943-7952. http://dx.doi.org/10.1128/JVI.00549-10.
27. Abdul-Jawad S, Ondondo B, van Hateren A, Gardner A, Elliott T, Korber B, Hanke T. 2015. Increased valency of conserved-mosaic vaccines enhances the breadth and depth of epitope recognition. Mol Ther 24:375-384. http://dx.doi.org/10.1038/mt.2015.210.
28. Gogolak P, Simon A, Horvath A, Rethi B, Simon I, Berkics K, Rajnavolgyi E, Toth GK. 2000. Mapping of a protective helper T cell epitope of human influenza A virus hemagglutinin. Biochem Biophys Res Commun 270:190-198. http://dx.doi.org/10.1006/bbrc.2000.2384.
29. Delaloye J, Roger T, Steiner-Tardivel QG, Le Roy D, Knaup Reymond M, Akira S, Petrilli V, Gomez CE, Perdiguero B, Tschopp J, Pantaleo G, Esteban M, Calandra T. 2009. Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5, and the NALP3 inflammasome. PLoS Pathog 5: e1000480. http://dx.doi.org/10.1371/journal.ppat.1000480.
30. Altenburg AF, Kreijtz JHCM, de Vries RD, Song F, Fux R, Rimmelzwaan GF, Sutter G, Volz A. 2014. Modified vaccinia virus Ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases. Viruses 6:2735-2761. http://dx.doi.org/10.3390/v6072735.
31. Ito R, Ozaki YA, Yoshikawa T, Hasegawa H, Sato Y, Suzuki Y, Inoue R, Morishima T, Kondo N, Sata T, Kurata T, Tamura S. 2003. Roles of anti-hemagglutinin IgA and IgG antibodies in different sites of the respiratory tract of vaccinated mice in preventing lethal influenza pneumonia. Vaccine 21:2362-2371. http://dx.doi.org/10.1016/S0264-410X(03)00078-1.
32. Renegar KB, Small PA, Jr, Boykins LG, Wright PF. 2004. Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J Immunol 173:1978-1986. http://dx.doi.org/10.4049/jimmunol.173.3.1978.
33. Wagner DK, Clements ML, Reimer CB, Snyder M, Nelson DL, Murphy BR. 1987. Analysis of immunoglobulin G antibody responses after administration of live and inactivated influenza A vaccine indicates that nasal wash immunoglobulin G is a transudate from serum. J Clin Microbiol 25:559-562.
34. Sealy R, Surman S, Hurwitz JL, Coleclough C. 2003. Antibody response to influenza infection of mice: different patterns for glycoprotein and nucleocapsid antigens. Immunology 108:431-439. http://dx.doi.org/10.1046/j.1365-2567.2003.01615.x.
35. Tamura S, Kurata T. 2004. Defense mechanisms against influenza virus infection in the respiratory tract mucosa. Jpn J Infect Dis 57:236-247.